Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 12:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 5,570 matching trials from the live ClinicalTrials.gov search.
Conditions
Healthy Participants
Interventions
Povorcitinib, Levonorgestrel/Ethinyl estradiol
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Chronic Lymphocytic Leukemia (CLL), Leukaemia, Lymphocytic, Chronic
Interventions
Ofatumumab, Bendamustine
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
6
States / cities
Tuscon, Arizona • Aurora, Colorado • Fort Myers, Florida + 3 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dose-Finding Study of Lyophilized Shigella Sonnei 53G Challenge Strain

NCT02816346
Conditions
Healthy
Interventions
Shigella sonnei 53G
Biological
Lead sponsor
PATH
Other
Eligibility
18 Years to 49 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Formative Study to Explore the Sensory Perceptions of Vaginal Product Users

NCT01334827
Conditions
Microbicide Delivery System Acceptability
Interventions
high volume gel, low volume gel, vaginal film
Other
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Providence, Rhode Island
Conditions
Benign Prostatic Hyperplasia
Interventions
talaporfin sodium, Saline, Drug Activator 100 J/cm, Drug Activator 200 J/cm
Drug · Device
Lead sponsor
Light Sciences Oncology
Industry
Eligibility
40 Years and older · Male only
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
41
States / cities
Anniston, Alabama • Huntsville, Alabama • Anchorage, Alaska + 37 more
Conditions
Neuroblastoma, Refractory Neuroblastoma, Relapsed Neuroblastoma, Relapsed Osteosarcoma, Refractory Osteosarcoma
Interventions
Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate
Combination Product
Lead sponsor
Emory University
Other
Eligibility
12 Months and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Diabetes Type 2
Interventions
Insulin-Levemir, Exenatide-Bayetta, Insulin-Levemir and Exenatide-Bayetta, SenseWear Pro3® armband, DexCom CGM
Drug · Device
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 90 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Conditions
Cutaneous T-cell Lymphoma, Mycosis Fungoides, Sezary Syndrome
Interventions
Rosiglitazone and Bexarotene
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Glioblastoma
Interventions
Standard surgery, Intraoperative radiotherapy, Radiochemotherapy, Temozolomide
Procedure · Radiation · Drug
Lead sponsor
Universitätsmedizin Mannheim
Other
Eligibility
18 Years to 80 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
5
States / cities
Phoenix, Arizona • Maywood, Illinois • Lake Success, New York + 2 more
Conditions
HIV Infection
Interventions
PCC, Emtricitabine/tenofovir (FTC/TDF (Truvada®))
Behavioral · Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
15 Years to 17 Years · Male only
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 3 more
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Mechanisms of Probiotics and Antibiotic-Associated Diarrhea

NCT04414722
Conditions
Antibiotic-associated Diarrhea
Interventions
Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet, BB-12, Control Yogurt
Drug · Biological · Other
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 65 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Bortezomib, Dexamethasone, Doxil
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
5
States / cities
Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 2 more
Conditions
Hepatocellular Carcinoma
Interventions
Cabozantinib, Sorafenib, Atezolizumab
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
837 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
33
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 26 more
Conditions
HIV Infections
Interventions
Ritonavir, Nelfinavir mesylate, Saquinavir, Nevirapine, Lamivudine, Stavudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Years to 22 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Miami, Florida + 13 more
Conditions
Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma, HTLV-1 Infection
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide, Lenalidomide, Multigated Acquisition Scan, Positron Emission Tomography, Prednisone, Vincristine Sulfate
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
19
States / cities
Atlanta, Georgia • City of Saint Peters, Missouri • Creve Coeur, Missouri + 11 more
Conditions
Fertility Preservation
Interventions
OCP pause
Other
Lead sponsor
Shady Grove Fertility Reproductive Science Center
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Orange, Connecticut • Rockville, Maryland • New York, New York
Completed Not applicable Interventional Results available

Comparison of Liquid Kaletra and Low Dose Kaletra Tablets

NCT00762320
Conditions
HIV Infections
Interventions
Low dose Kaletra tablets
Drug
Lead sponsor
Phoenix Children's Hospital
Other
Eligibility
3 Years to 18 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Acute Ischemic Stroke
Interventions
Endovascular Thrombectomy, Medical Management
Device · Other
Lead sponsor
Amrou Sarraj
Other
Eligibility
18 Years to 85 Years
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Chicago, Illinois • Kansas City, Kansas • St Louis, Missouri + 3 more
Conditions
Atherosclerosis
Interventions
Rosuvastatin 10 mg, Darapladib 160 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
20 Years to 64 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Glendale, California
Conditions
Lumbar Spine Disease, Lumbar Spondylolisthesis, Lumbar Spine Instability, Lumbar Spondylosis, Degenerative Disc Disease
Interventions
OSTEOAMP, Infuse
Other · Device
Lead sponsor
Bioventus LLC
Industry
Eligibility
21 Years to 80 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
9
States / cities
New Haven, Connecticut • Wichita, Kansas • Paducah, Kentucky + 6 more
Conditions
HIV Infections
Interventions
Atazanavir, Lamivudine/Zidovudine, Efavirenz
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
28
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 24 more
Conditions
Solid Tumors, Lymphoma
Interventions
LMP744, Ondansetron, Olanzapine, Lorazepam, Diphenoxylate hydrocholoride (HCL) + Atropine Sulfate, Loperamide, Diphenhydramine, Steroid, Epinephrine
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Bethesda, Maryland • Pittsburgh, Pennsylvania
Conditions
Pancreatic Cancer
Interventions
Chemotherapy, Chemotherapy + ChemoRadiotherapy
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Enrolling by invitation Phase 4 Interventional

Houston Emergency Opioid Engagement System

NCT03396276
Conditions
Opioid Use Disorder
Interventions
Suboxone, Brief counseling in the ED, Referral to outpatient treatment, Follow-up coaching
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
1
States / cities
Houston, Texas